American Century Companies Inc. Sells 258,950 Shares of Novo Nordisk A/S $NVO

American Century Companies Inc. trimmed its holdings in Novo Nordisk A/S (NYSE:NVO) by 20.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,022,211 shares of the company’s stock after selling 258,950 shares during the quarter. American Century Companies Inc.’s holdings in Novo Nordisk A/S were worth $70,982,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Park Square Financial Group LLC bought a new stake in Novo Nordisk A/S during the 4th quarter valued at about $29,000. Transce3nd LLC bought a new stake in Novo Nordisk A/S during the 4th quarter valued at about $33,000. North Capital Inc. bought a new stake in Novo Nordisk A/S during the 1st quarter valued at about $27,000. Copeland Capital Management LLC increased its stake in Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock valued at $27,000 after purchasing an additional 255 shares in the last quarter. Finally, Stone House Investment Management LLC bought a new stake in Novo Nordisk A/S during the 1st quarter valued at about $30,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $53.81 on Tuesday. The firm’s 50-day moving average price is $64.52 and its 200-day moving average price is $70.02. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The company has a market cap of $240.26 billion, a PE ratio of 14.78, a PEG ratio of 1.80 and a beta of 0.63. Novo Nordisk A/S has a 52-week low of $45.05 and a 52-week high of $139.74.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The business had revenue of $11.69 billion during the quarter, compared to analysts’ expectations of $77.51 billion. As a group, analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th will be given a $0.4119 dividend. The ex-dividend date is Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 45.05%.

Wall Street Analyst Weigh In

NVO has been the subject of a number of analyst reports. Hsbc Global Res lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 31st. BNP Paribas Exane upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 price objective for the company in a research note on Wednesday, August 13th. Dbs Bank lowered shares of Novo Nordisk A/S to a “sell” rating in a research note on Friday, April 25th. BNP Paribas upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research note on Wednesday, August 13th. Finally, HSBC downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $57.00 price target on the stock. in a report on Thursday, July 31st. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $83.75.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.